Feasibility of Semaglutide in Advanced Lung Disease

AI Simplified Original

AI-powered

Recruiting

18 years - 80 years

All

Phase 1/2

8 participants needed

1 Location

Brief description of study

The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease.

The main question[s] it aims to answer are:

Are patients with advanced lung disease able to tolerate semaglutide therapy?
Are we able to titrate semaglutide therapy to a target weight?

Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a blood draw before and after 12-weeks of semaglutide therapy. While on therapy, subjects will be surveyed regarding any adverse events or side effects.

Detailed description of study

This is a small open-label pilot clinical trial of semaglutide in adults (age 18 or older, n=8) with obesity (BMI≥30 kg/m2), and chronic advanced lung disease (interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension requiring supplemental oxygen on exertion). This study will evaluate medication adherence and side effects to determine semaglutide tolerability. Markers of physical function and pulmonary function will be evaluated before therapy and after 12 weeks of therapy to determine the effect of semaglutide on function. Measures of fat and muscle, will be performed before therapy and after 12 weeks of therapy to evaluate how semaglutide alters body composition in this population. Study participants will be monitored for 12 weeks while receiving semaglutide therapy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
Age: 18 years - 80 years
Gender: All

Inclusion Criteria:

Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension
Age > 18
BMI > 30 kg/m2
Requires supplemental oxygen on exertion
Stable treatment regimen X 90 days
Use of disease-modifying therapy

Exclusion Criteria:

Diabetes
Pregnant or Breastfeeding
Recent weight loss
Recent or chronic GI complaints
History of gastroparesis
History of scleroderma
Hospitalized at time of evaluation
Use of weight loss medication in last 90 days
Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2)
Uncontrolled thyroid disease
History of acute/chronic pancreatitis
Prior suicide attempt
Suicidal ideation in last 90 days
Presence of a pacemaker or defibrillator

This study investigates the feasibility and tolerability of an investigational medication in patients with advanced lung disease. Advanced lung diseases included in the study are interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, and pulmonary hypertension. The purpose of this study is to assess whether patients can tolerate the investigational medication and if it can be adjusted to achieve a target weight.

Participants will undergo various assessments, including pulmonary function tests, physical function tests, and body composition measurements. Blood samples will be collected before and after 12 weeks of therapy. During the treatment period, participants will be asked about any adverse events or side effects they experience.

Who can participate: Adults aged 18 and older with a BMI over 30 and a diagnosis of interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension requiring supplemental oxygen on exertion can participate. Participants must have a stable treatment regimen for at least 90 days and be on disease-modifying therapy.
Study details: Participants will receive semaglutide, an investigational medication, for 12 weeks. They will take part in assessments such as pulmonary and physical function tests, as well as body composition measurements. They will also provide blood samples and report any side effects during the 12-week treatment period.
Study timelines and visits: The study will last 12 weeks. Visits are not specified.

Updated on 21 Apr 2026. Study ID: 23-0134

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

View email

Phone

View phone

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Please provide your preferred way of contact

Other language

By Submitting your information, you agree that your details may be shared with the selected study site and handled in accordance with this Website's Privacy Policy (see link in footer). You may be contacted by email, text message, or phone regarding this study and other research opportunities that may be of interested to you. You can unsubscribe from these communications at any time. Message and data rates may apply.

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.